ArticlePorcine health management2025
Porcine reproductive and respiratory syndrome virus 2 in Europe: neither wild nor tamed.
Article in Porcine health management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cross-Protection in PRRSV: Mechanisms, Limitations, and Implications for Vaccine Design.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPorcine reproductive and respiratory syndrome virus (PRRSV) exhibits a marked geographical clustering, with PRRSV-2 being predominantly found in North America and Asia. Its presence in Europe remains extremely limited and mainly represented by vaccine-like strains, belonging to sublineage 5.1. While the use of this vaccine is possible and applied in Northern Europe, its detection in Southern European countries has been largely anecdotal.
resultsIn the present study, we report the first confirmed case of PRRSV-2 detection in Italy, identifying two independent introduction events with no clear epidemiological link. A deeper evaluation of the overall epidemiological end evolutionary patterns of MLV-derived strains was performed to elucidate the present study findings. The phylogenetic and molecular analyses revealed significant genetic variability among vaccine-derived strains, with pairwise genetic distances exceeding 8% and an estimated evolutionary rate of ~10
conclusionsContrary to expectations, PRRSV-2 vaccine-like strains exhibited transmission dynamics comparable to field strains. Their divergence, potential for adaptation, and reversion to virulence raise concerns about their long-term epidemiological and clinical impact. Given the scarcity of PRRSV-2 field strain reports in Europe, further surveillance and sequencing efforts are crucial to assess its true prevalence, evolutionary potential, and implications for swine health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.